VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.

At a glance

Company: VERAXA Biotech
Ticker: NASDAQ: VRXA

Key figures

BiTAC-based T-cell engager programs: four
Bispecific ADC programs: two
Non-BiTAC assets available for partnering: two
VXA-102 readiness target: early 2028

Products and programs

BiTAC platform
VXA-102
BiTAC-based T-cell engager programs
Bispecific ADC programs
Non-BiTAC assets

To view the full press release, visit https://ibn.fm/xT F 5q

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

VERAXA Biotech reported progress across its pipeline and partnering plans for the first half of 2026. The company says its portfolio includes four BiTAC-based T-cell engager programs for solid tumors, two bispecific ADC programs and two non-BiTAC assets available for partnering. VERAXA plans to focus investment on its BiTAC portfolio and seek partnerships or other ways to monetize selected non-BiTAC programs. It aims to bring lead candidate VXA-102 to IND/CTA readiness by early 2028. The company also reported interest from potential pharmaceutical partners, citing discussions at the BIO International Convention and other scientific meetings. VERAXA says it will continue adjusting its pipeline and partnering approach as it develops cancer therapies.

Key takeaways

VERAXA says its pipeline includes four BiTAC-based T-cell engager programs, two bispecific ADC programs and two non-BiTAC assets.
The company plans to prioritize BiTAC investment and seek to monetize selected non-BiTAC programs.
VERAXA aims to advance lead candidate VXA-102 to IND/CTA readiness by early 2028.
The company reported potential partner interest following discussions at industry and scientific meetings.

SEC filings

Earlier from VERAXA Biotech AG

Back to News Center